Recruiting
Phase 1

GvHD Prevention

Sponsor:

Tr1X, Inc.

Code:

NCT06462365

Conditions

Hematologic Malignancy

GvHD

GVHD,Acute

GVHD, Chronic

Hematopoietic Stem Cell Transplant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TRX103

Study Details

Brief summary:

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

Conditions

Hematologic Malignancy

GvHD

GVHD,Acute

GVHD, Chronic

Hematopoietic Stem Cell Transplant

Study ID

NCT06462365

Start date

Apr 8, 2024

Status verified date

Oct, 2024

Completion date

Apr 15, 2027

Anticipated

Primary completion date

Apr 15, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)
2. Males and Females Age ≥ 18 years.
3. Weight of ≥ 35 Kg.
4. Karnofsky performance status ≥ 70 %.
5. Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.
6. Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.
7. Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.
8. Have adequate organ function.
9. Subjects > 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score < 5.
10. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.

Exclusion Criteria:

1. Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.
2. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.
3. HIV positive.
4. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.
5. Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.
6. Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and/or have not recovered from treatment related toxicities.
7. Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.
8. Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).
9. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.

Study Design

Enrollment

36 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: TRX-103

TRX-103 will be infused on time post hematopoietic stem cell transplant (HSCT).

Interventions

TRX103

TRX103 infusion via central line.

Primary outcome measure

  • Safety and tolerability of TRX103 cell infusion through incidence of Adverse events. [ Time Frame: Up to a year ]
  • Safety of TRX103 determined by stem cell engraftment and donor chimerism after HSCT measured by absolute neutrophil counts and percent donor chimerism. [ Time Frame: Up to day 42 ]
  • Safety of TRX103 determined by negative Replication Competent Lentivirus (RCL). [ Time Frame: At 3-month, 6-month, and 1-year. ]

Central Contacts and Locations

Central contacts

Locations

City of Hope

Recruiting

Duarte, California, United States, 91010

Contacts

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

University of Minnesota

Recruiting

Minneapolis, Minnesota, United States, 55455

Contacts

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 10065

Contacts

Miguel-Angel Perales, MD

646-608-3757peralesm@MSKCC.org

Fred Hutchinson Cancer Center

Recruiting

Seattle, Washington, United States, 98109

Contacts

More Information

Sponsor

Tr1X, Inc.

Last update posted

Apr 15, 2025

Last verified

Oct, 2024

Keywords

  • AML
  • CMML
  • Stem Cell Transplant
  • B-ALL
  • T-ALL
  • Acute GvHD
  • Graft versus Host Disease
  • Chronic GvHD
  • MDS
  • Cellular Therapy
  • Autoimmune
  • T regulatory cells

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Tr1X, Inc. on 2025-04-15.